- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
This study is looking at a new treatment combination for certain advanced cancers, including lung, head and neck, and bladder cancer. Researchers want to see if combining two new drugs with an existing one, Pembrolizumab, can help shrink tumours and is safe for patients.
For: Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) · Metastatic Urothelial Bladder Cancer (mUBC) · Metastatic Non-Small Cell Lung Cancer (NSCLC)Spain - Active not recruitingPHASE3
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
This study looks at a new combination treatment for advanced melanoma, a type of skin cancer. It compares giving a new drug called IO102-IO103 alongside an existing drug, pembrolizumab, with giving pembrolizumab alone. The aim is to see if the combination helps patients live longer without their cancer getting worse.
For: Metastatic Melanoma · Unresectable MelanomaUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors
This study is looking at a new treatment before and after surgery for certain skin cancers and head and neck cancers. It combines two new drugs (IO102-IO103) with an existing cancer drug (Keytruda) to see how effectively they shrink tumors and improve patient outcomes.
For: Melanoma and squamous cell carcinoma of the head and neckSpain · Germany · Denmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma
This study is looking at a new combination of medicines (IO102-IO103 with pembrolizumab, also known as KEYTRUDA) for people with advanced melanoma that hasn't been treated before. It compares this combination to pembrolizumab alone to see if it works better at stopping the cancer from growing.
For: Previously untreated · unresectable · or metastatic melanomaHungary · Denmark · Poland